Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis

American Journal of Medicine

Volumn 122, Issue 2 SUPPL., 2009, Pages

  Bilezikian, John P ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Bisphosphonates; Bone mineral density; Clinical trials; Fracture; Osteoporosis; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; LONG TERM CARE; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 58949102427     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.12.003     Document Type: Article

References (27)

1. National Osteoporosis Foundation. Fast Facts on Osteoporosis [fact sheet]. http://www.nof.org/osteoporosis/diseasefacts.htm Accessed July 15, 2008
2. Cummings S.R., and Melton III L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1767
3. Kanis J.A., and Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16 (2005) 229-238
4. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., and Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22 (2007) 465-475
5. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis (2008), National Osteoporosis Foundation, Washington, DC. http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf Accessed March 25, 2008
6. WHO Study Group on Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group (1994), World Health Organization, Geneva, Switzerland WHO Technical Report Series No. 843
7. Kanis J.A., and WHO Scientific Group. Assessment of Osteoporosis at the Primary Health-Care Level. [technical report] (2007), World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
8. FRAX (WHO Fracture Risk Assessment Tool). Sheffield, United Kingdom: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. http://www.shef.ac.uk/FRAX Accessed November 10, 2008
9. Chapurlat R.D., and Delmas P.D. Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2 (2006) 211-219
10. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
11. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
12. Black D.M., Schwartz A.V., Ensrud K.E., et al., FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX). A randomized trial. JAMA 296 (2006) 2927-2938
13. Schnitzer T., Bone H.G., Crepaldi G., et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12 (2000) 1-12
14. Rizzoli R., and The Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17 (2002) 1988-1996
15. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282 (1999) 1344-1352
16. Reginster J.-Y., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11 (2000) 83-91
17. Sörensen O.H., Crawford G.M., Mulder H., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32 (2003) 120-126
18. Mellström D.D., Sörensen O.H., Goemaere S., Roux C., Johnson T.D., and Chines A.A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75 (2004) 462-468
19. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344 (2001) 333-340
20. Brown J.P., Kendler D.L., McClung M.R., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71 (2002) 103-111
21. Harris S.T., Watts N.B., Li Z., Chines A.A., Hanley D.A., and Brown J.P. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 20 (2004) 757-764
22. Delmas P.D., McClung M.R., Zanchetta J.R., et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42 (2008) 36-42
23. Chesnut III C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
24. Reginster J.-Y., Adami S., Lakatos P., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65 (2006) 654-661
25. Delmas P.D., Adami S., Strugala C., et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration Study. Arthritis Rheum 54 (2006) 1838-1846
26. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
27. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357 (2007) 1799-1809